medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/ms2024-051medsovet-8123Research ArticleЗАБОЛЕВАНИЯ КОЖИDERMAL DISEASESОпыт применения ингибитора интерлейкина-23 гуселькумаба у пациентов с тяжелым псориазом и влияние заболевания на психоэмоциональный фонExperience with interleukin-23 inhibitor guselkumab using in patients with severe psoriasis and the impact of the disease on the psycho-emotional backgroundhttps://orcid.org/0000-0002-5885-4872СвечниковаЕ. В.SvechnikovaE. V.

Свечникова Елена Владимировна - д.м.н., профессор кафедры кожных и венерических болезней, РОСБИОТЕХ; заведующая отделением дерматовенерологии и косметологии, Поликлиника №1 Управления делами Президента РФ.

125080, Москва, Волоколамское шоссе, д. 11; 119002, Москва, пер. Сивцев Вражек, д. 26/28

Elena V. Svechnikova - Dr. Sci. (Med.), Professor of the Department of Skin and Sexually Transmitted Diseases, Russian Biotechnological University (BIOTECH University); Head of the Department of Dermatology and Cosmetology, Polyclinic No. 1 of the Administrative Department of the Russian Federation.

11, Volokolamskoe Shosse, Moscow, 125080; 26/28, Sivtsev Vrazhek Lane, Moscow, 119002

elene-elene@bk.ruhttps://orcid.org/0000-0001-5694-2847ЖуфинаС. Е.ZhufinaS. E.

Жуфина Светлана Евгеньевна - врач-дерматовенеролог отделения дерматовенерологии и косметологии.

119002, Москва, пер. Сивцев Вражек, д. 26/28

Svetlana E. Zhufina - Dermatovenerologist of the Department of Dermatology and Cosmetology, Polyclinic No. 1 of the Administrative Department of the Russian Federation.

26/28, Sivtsev Vrazhek Lane, Moscow, 119002

svetlanagufina@gmail.comПоликлиника №1 Управления делами Президента Российской Федерации; Российский биотехнологический университет (РОСБИОТЕХ)Russian FederationПоликлиника №1 Управления делами Президента Российской ФедерацииRussian Federation202406032024026874Copyright © Свечникова Е.В., Жуфина С.Е., 20242024Свечникова Е.В., Жуфина С.Е.Svechnikova E.V., Zhufina S.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/8123

Псориаз – хроническое иммуноопосредованное заболевание, не только приводящее к поражению кожи и ее придатков, но и ассоциированное с сопутствующими системными заболеваниями, включая поражение опорно-двигательного аппарата, сердечно-сосудистые патологии, заболевания почек, метаболический синдром и изменения со стороны нервной системы. Не так давно был введен термин, объединяющий псориаз и сопутствующие коморбидные заболевания, – псориатическая болезнь. В последнее время особое внимание уделяется оценке психоэмоционального состояния и качеству жизни больных псориазом, которые несут бремя хронического заболевания. Отмечено, что любое кожное заболевание существенно ухудшает качество и уровень жизни пациента и может привести к социальной и профессиональной стигматизации и дискриминации, ряду ограничений. Псориатическая болезнь признается мультисистемным воспалительным заболеванием, рекомендуется целостный подход к лечению с упором на сопутствующие заболевания, включая психическое здоровье, психосоциальное благополучие и качество жизни. Дерматологический индекс качества жизни (DLQI) – один из самых удобных, позволяющий оценить степень тяжести бремени хронических кожных заболеваний, в том числе псориаза, на повседневную деятельность человека. Выявлена корреляция между степенью тяжести псориаза, наличием сопутствующих заболеваний, особенно псориатического артрита, и уровнем DLQI. Индекс DLQI выше у пациентов с псориазом среднетяжелого и тяжелого течения; легкой степени тяжести (низкий индекс PASI), но с поражением социально значимых участков кожного покрова (лицо, кисти и стопы, волосистая часть головы, половые органы, ногтевые пластины); у имеющих активные проявления псориатической болезни в виде сопутствующих заболеваний, что усложняет выбор препарата для лечения. Доступность и эффективность схем лечения современными препаратами играют не последнюю роль в психоэмоциональном состоянии пациентов. Сегодня в лечении псориаза активно используются биологические препараты, которые обладают рядом преимуществ в сравнении с препаратами базисной противовоспалительной и фототерапии и, соответственно, имеют большую эффективность и представляют ценность для пациентов, которые в повседневной жизни испытывают эмоциональный дискомфорт от хронического заболевания кожи. Целью данной статьи было изучение распространенности и характера патологий психического и психиатрического характера у пациентов с псориазом, возможного улучшения DLQI у пациентов с псориазом, использующих биологический препарат из группы ингибиторов интерлейкина-23 гуселькумаб.

Psoriasis is a chronic immune-mediated disease that leads not only to damage to the skin and its appendages, but is also associated with concomitant systemic diseases, including damage to the musculoskeletal system, cardiovascular pathologies, kidney disease, metabolic syndrome and changes in the nervous system. Not long ago, a term was introduced to unite psoriasis and concomitant comorbid diseases – psoriatic disease. Recently, special attention has been paid to assessing the psychoemotional state and quality of life of patients with psoriasis who bear the burden of a chronic disease. It is no secret that any skin disease significantly worsens the quality and standard of life of the patient and can lead to social and professional stigma and discrimination, and a number of restrictions. Psoriatic disease is recognized as a multisystem inflammatory disease and a holistic approach to treatment is recommended, focusing on comorbidities, including mental health, psychosocial well-being and quality of life. The Dermatological Life Quality Index (DLQI) is one of the most convenient indices that allows you to assess the severity of the burden of chronic skin diseases, including psoriasis, on a person’s daily activities; a correlation was found between the severity of psoriasis, the presence of concomitant diseases, especially psoriatic arthritis and the DLQI level. DLQI is higher in patients with moderate to severe psoriasis, in patients with mild psoriasis (low PASI index), but with damage to socially significant areas of the skin (face, hands and feet, scalp, genitals, nail plates), in patients with active manifestations of psoriatic disease in the form of concomitant diseases, which complicates the choice of drug for treatment. The availability, effectiveness, and treatment regimens of modern drugs play an important role in the psycho-emotional state of patients. Today the biological drugs have been actively used in the treatment of psoriasis, which have a number of advantages compared to drugs of basic anti-inflammatory therapy and phototherapy, and, accordingly, are more effective and are of value for patients who experience emotional discomfort from a chronic skin disease in everyday life. The purpose of this article was to study the prevalence and nature of mental and psychiatric pathologies in patients with psoriasis, the possible improvement of DLQI in patients with psoriasis using a biological drug from the group of interleukin-23 inhibitors guselkumab.

псориатическая болезньсистемное воспалениепсориазгуселькумабкачество жизниpsoriatic diseasesystemic inflammationpsoriasisguselkumabquality of lifeReferencesBai F, Li GG, Liu Q, Niu X, Li R, Ma H. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. J Immunol Res. 2019:2546161. https://doi.org/10.1155/2019/2546161.Bai F, Li GG, Liu Q, Niu X, Li R, Ma H. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. J Immunol Res. 2019:2546161. https://doi.org/10.1155/2019/2546161.Armstrong AW, Bohannan B, Mburu S, Coates LC, Ogdie A, Alarcon I et al. Patient Perspectives on Psoriatic Disease Burden: Results from the Global Psoriasis and Beyond Survey. Dermatology. 2023;239(4):621–634. https://doi.org/10.1159/000528945.Armstrong AW, Bohannan B, Mburu S, Coates LC, Ogdie A, Alarcon I et al. Patient Perspectives on Psoriatic Disease Burden: Results from the Global Psoriasis and Beyond Survey. Dermatology. 2023;239(4):621–634. https://doi.org/10.1159/000528945.Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700–712. https://doi.org/10.1136/annrheumdis-2020-217159.Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700–712. https://doi.org/10.1136/annrheumdis-2020-217159.Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161–201. https://doi.org/10.1016/j.jaad.2019.08.049.Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161–201. https://doi.org/10.1016/j.jaad.2019.08.049.Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Csörgö Z, Boonen H et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461–2498. https://doi.org/10.1111/jdv.16915.Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Csörgö Z, Boonen H et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461–2498. https://doi.org/10.1111/jdv.16915.De Ruiter CC, Rustemeyer T. Biologics Can Significantly Improve Dermatology Life Quality Index (DLQI) in Psoriatic Patients: A Systematic Review. Psoriasis (Auckl). 2022;12:99–112. https://doi.org/10.2147/PTT.S356568.De Ruiter CC, Rustemeyer T. Biologics Can Significantly Improve Dermatology Life Quality Index (DLQI) in Psoriatic Patients: A Systematic Review. Psoriasis (Auckl). 2022;12:99–112. https://doi.org/10.2147/PTT.S356568.Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk Factors for the Development of Psoriasis. Int J Mol Sci. 2019;20(18):4347. https://doi.org/10.3390/ijms20184347.Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk Factors for the Development of Psoriasis. Int J Mol Sci. 2019;20(18):4347. https://doi.org/10.3390/ijms20184347.Wu JJ, Kavanaugh A, Lebwohl MG, Gniadecki R, Merola JF. Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2022;36(6):797–806. https://doi.org/10.1111/jdv.18044.Wu JJ, Kavanaugh A, Lebwohl MG, Gniadecki R, Merola JF. Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2022;36(6):797–806. https://doi.org/10.1111/jdv.18044.Bernardini N, Skroza N, Prevete E, Marraffa F, Proietti I, Tolino E et al. Guselkumab for the treatment of severe plaque psoriasis in a schizophrenia patient. Dermatol Reports. 2022;14(4):9476. https://doi.org/10.4081/dr.2022.9476.Bernardini N, Skroza N, Prevete E, Marraffa F, Proietti I, Tolino E et al. Guselkumab for the treatment of severe plaque psoriasis in a schizophrenia patient. Dermatol Reports. 2022;14(4):9476. https://doi.org/10.4081/dr.2022.9476.Blake T, Gullick NJ, Hutchinson CE, Barber TM. Psoriatic disease and body composition: A systematic review and narrative synthesis. PLoS ONE. 2020;15(8):e0237598. https://doi.org/10.1371/journal.pone.0237598.Blake T, Gullick NJ, Hutchinson CE, Barber TM. Psoriatic disease and body composition: A systematic review and narrative synthesis. PLoS ONE. 2020;15(8):e0237598. https://doi.org/10.1371/journal.pone.0237598.Van de Kerkhof PC. From Empirical to Pathogenesis-Based Treatments for Psoriasis. J Invest Dermatol. 2022;142(7):1778–1785. https://doi.org/10.1016/j.jid.2022.01.014.Van de Kerkhof PC. From Empirical to Pathogenesis-Based Treatments for Psoriasis. J Invest Dermatol. 2022;142(7):1778–1785. https://doi.org/10.1016/j.jid.2022.01.014.Chan TC, Hawkes JE, Krueger JG. Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment. Ther Adv Chronic Dis. 2018;9(5):111–119. https://doi.org/10.1177/2040622318759282.Chan TC, Hawkes JE, Krueger JG. Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment. Ther Adv Chronic Dis. 2018;9(5):111–119. https://doi.org/10.1177/2040622318759282.Yang EJ, Smith MP, Ly K, Bhutani T. Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis. Drug Des Devel Ther. 2019;13:1993–2000. https://doi.org/10.2147/DDDT.S137588.Yang EJ, Smith MP, Ly K, Bhutani T. Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis. Drug Des Devel Ther. 2019;13:1993–2000. https://doi.org/10.2147/DDDT.S137588.Light JG, Su JJ, Feldman SR. Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis. Clin Cosmet Investig Dermatol. 2021;14:55–63. https://doi.org/10.2147/CCID.S235242.Light JG, Su JJ, Feldman SR. Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis. Clin Cosmet Investig Dermatol. 2021;14:55–63. https://doi.org/10.2147/CCID.S235242.Yang J, Hu K, Li X, Hu J, Tan M, Zhang M et al. Psoriatic Foot Involvement is the Most Significant Contributor to the Inconsistency Between PASI and DLQI: A Retrospective Study from China. Clin Cosmet Investig Dermatol. 2023;16:443–451. https://doi.org/10.2147/CCID.S396997.Yang J, Hu K, Li X, Hu J, Tan M, Zhang M et al. Psoriatic Foot Involvement is the Most Significant Contributor to the Inconsistency Between PASI and DLQI: A Retrospective Study from China. Clin Cosmet Investig Dermatol. 2023;16:443–451. https://doi.org/10.2147/CCID.S396997.Strober B, Ryan C, van de Kerkhof P, van der Walt J, Kimball AB, Barker J, Blauvelt A. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82(1):117–122. https://doi.org/10.1016/j.jaad.2019.08.026.Strober B, Ryan C, van de Kerkhof P, van der Walt J, Kimball AB, Barker J, Blauvelt A. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82(1):117–122. https://doi.org/10.1016/j.jaad.2019.08.026.Paudyal P, Apfelbacher C, Jones C, Siddiqui S, El-Turki A, DeGiovanni C, Smith H. “DLQI Seems to be ‘Action’, and Skindex-29 Seems to be ‘Emotion’”: Qualitative Study of the Perceptions of Patients with Psoriasis or Eczema on Two Common Dermatology-specific Quality of Life Measures. Acta Derm Venereol. 2020;100(8):adv00105. https://doi.org/10.2340/00015555-3417.Paudyal P, Apfelbacher C, Jones C, Siddiqui S, El-Turki A, DeGiovanni C, Smith H. “DLQI Seems to be ‘Action’, and Skindex-29 Seems to be ‘Emotion’”: Qualitative Study of the Perceptions of Patients with Psoriasis or Eczema on Two Common Dermatology-specific Quality of Life Measures. Acta Derm Venereol. 2020;100(8):adv00105. https://doi.org/10.2340/00015555-3417.Armstrong AW, Bohannan B, Mburu S, Coates LC, Ogdie A, Alarcon I et al. Patient Perspectives on Psoriatic Disease Burden: Results from the Global Psoriasis and Beyond Survey. Dermatology. 2023;239(4):621–634. https://doi.org/10.1159/000528945.Armstrong AW, Bohannan B, Mburu S, Coates LC, Ogdie A, Alarcon I et al. Patient Perspectives on Psoriatic Disease Burden: Results from the Global Psoriasis and Beyond Survey. Dermatology. 2023;239(4):621–634. https://doi.org/10.1159/000528945.Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417. https://doi.org/10.1016/j.jaad.2016.11.041.Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417. https://doi.org/10.1016/j.jaad.2016.11.041.

The authors declare that there are no conflicts of interest present.